12:06 PM EST, 11/15/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Friday results from part B of a phase 2 trial assessing combinations of tobevibart and elebsiran to treat chronic hepatitis B showed promising rates of hepatitis B surface antigen loss in participants with low baseline levels, particularly when combined with pegylated interferon alfa.

The study included 51 participants receiving tobevibart and elebsiran alone, and 27 receiving the drugs plus pegylated interferon alfa. In patients with baseline HBsAg below 1,000 IU/mL, 39% and 46% achieved HBsAg loss with the two-drug and three-drug regimens, respectively.

The primary endpoints of the study included HBsAg seroclearance and treatment-emergent adverse events at end of treatment.

The safety profile was consistent with previous studies, with no new concerns identified.

Vir Biotechnology ( VIR ) said it would present detailed results at The Liver Meeting in San Diego on Nov. 18. The company anticipates functional cure data in Q2 2025, which will be crucial for determining next steps in clinical development.

Chronic hepatitis B is an inflammatory liver disease due to the hepatitis B virus, the company said.

Price: 7.99, Change: -0.65, Percent Change: -7.55